Mucin Level as a Potential Biomarker for Breast Cancer Diagnosis
Abstract
Background: Breast cancer is the second leading cause of cancer death and a health problem worldwide. Secreted mucins are upregulated in ductal adenocarcinoma of the breast, however, the use of mucin as breast cancer biomarker has not been established before. This study aimed to determine the use of mucin level as a potential biomarker for breast cancer diagnosis.
Materials and methods: This was a retrospective, cross-section study involving 40 women subjects with breast cancer. Mucin level was examined with a combination of Alcian blue/periodic acid Schiff (AB/PAS) technique applied to each specimen. The results obtained were statistically analyzed using SPSS.
Results: Results of neutral mucin detection showed that among breast cancer subjects, 16 cases (40%) were neutral mucin score (+), 23 cases (57.5%) were neutral mucin score (++), and 1 case (2.5%) was neutral mucin score (+++). Meanwhile, 10 cases (25%) were acid mucin negative, 17 cases (42.5%) were acid mucin score (+), 11 cases (27.5%) were acid mucin score (++), and 2 cases (5%) were acid mucin score (+++). The most frequent type of mucin was the combination of acid and neutral mucin (30 cases; 75%) and neutral mucin were 10 cases (25%).
Conclusion: Detection of mucin level can be used as an alternative technique for the diagnosis of breast cancer complementary to other types of special stains.
Keywords: AB, PAS, breast cancer, histological grade, mucin level
Full Text:
PDFReferences
Widowati W, Jasaputra DK, Sumitro SB, Widodo MA, Afifah E, Rizal R, et al. Direct and indirect effect of TNFα and IFNγ toward apoptosis in breast cancer cells. Mol Cell Biomed Sci. 2018; 2(2): 60-9, CrossRef.
Purwanto I, Heiyanto DH, Ghozali A, Widodo I, Dwiprahasto I, Aryandono T, et al. Basal-like subgroup is associated with younger age, increased expression of androgen receptor, and worse prognosis, while non-basal-like subtype is associated with higher BMI in triple-negative breast cancer patients. Indones Biomed J. 2020; 12(4): 349-54, CrossRef.
Elgaili EM, Abuidris DO, Rahman M, Michalek AM, Mohammed SI. Breast cancer burden in central Sudan. Int J Womens Health. 2010; 2: 77-82, CrossRef.
Meiliana A, Dewi NM, Wijaya A. Cancer genetics and epigenetics in cancer risk assessment. Mol Cell Biomed Sci. 2021; 5(2): 41-61, CrossRef.
Senapati S, Das S, Batra SK. Mucin-interacting proteins: From function to therapeutics. Trends Biochem Sci. 2010; 35(4): 236-45, CrossRef.
Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the pathogenesis of breast cancer: Implications in diagnosis, prognosis and therapy. Biochim Biophys Acta. 2011; 1815(2): 224-40, CrossRef.
Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005; 18(10): 1295-304, CrossRef.
Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019; 41(2): 801-10, CrossRef.
Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. 6th ed. Churchill Livingstone: Philadelphia; 2008, article.
Walsh MD, McGuckin MA, Devine PL, Hohn BG, Wright RG. Expression of MUC2 epithelial mucin in breast carcinoma. J Clin Pathol. 1993; 46(10): 922-5, CrossRef.
Demichelis SO, Alberdi CG, Servi WJ, Isla-Larrain MT, Segal-Eiras A, Croce MV. Comparative immunohistochemical study of MUC1 and carbohydrate antigens in breast benign disease and normal mammary gland. Appl Immunohistochem Mol Morphol. 2010; 18(1): 41-50, CrossRef.
Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, et al. Breast cancer: Major risk factors and recent developments in treatment. Asian Pac J Cancer Prev. 2014; 15(8): 3353–8, CrossRef.
Thondavadi SR, Krishnamurthy J, Gubbanna VM. A case report of glycogen-rich clear cell carcinoma of breast. Indian J Pathol Microbiol. 2010; 53(2): 374–5, CrossRef.
Hanna WM, Corkill M. Mucins in breast carcinoma. Hum Pathol. 1988; 19(1): 11-4, CrossRef.
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020; 77(2): 181–5, CrossRef.
Budzik MP, Fudalej MM, Badowska-Kozakiewicz AM. Histopathological analysis of mucinous breast cancer subtypes and comparison with invasive carcinoma of no special type. Sci Rep 2021; 11(1): 5770, CrossRef.
Haltas H, Bayrak R, Yenidunya S, Kosehan D, Sen M, Akin K. Invasive lobular carcinoma with extracellular mucin as a distinct variant of lobular carcinoma: a case report. Diagn Pathol. 2012; 7: 91, CrossRef.
Khoury T, Malik D, Fan C, Tan D, Kulkarni S. Modified Alcian blue enhances the intraoperative diagnosis of sentinel lymph node metastasis in invasive lobular carcinoma: A prospective study. Arch Pathol Lab Med. 2010; 134(10): 1513-9, CrossRef.
Buijs JT, Cleton AM, Smit VT, Löwik CW, E Papapoulos S, Pluijm Gv. Prognostic significance of periodic acid-Schiff-positive patterns in primary breast cancer and its lymph node metastases. Breast Cancer Res Treat. 2004; 84(2): 117-30, CrossRef.
Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta. 1995; 1241(3): 407–23, CrossRef.
Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001; 6(3): 339–53, CrossRef.
Workman HC, Miller JK, Ingalla EQ, Kaur RP, Yamamoto DI, Beckett LA, et al. The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. Breast Cancer Res. 2009; 11(5): R70, CrossRef.
DOI: https://doi.org/10.21705/mcbs.v6i3.238
Copyright (c) 2022 Cell and BioPharmaceutical Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
Cell and BioPharmaceutical Institute
